We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synthomer Plc | LSE:SYNT | London | Ordinary Share | GB00BNTVWJ75 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -3.80 | -2.17% | 171.20 | 271,966 | 16:35:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 170.20 | 171.40 | 178.40 | 170.00 | 175.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 2.02B | -67M | -0.4096 | -4.18 | 286.24M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:24 | O | 4 | 171.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 31/10/2024 | 12:09 | ALNC |  Synthomer shares rise as third quarter as expected |
| 31/10/2024 | 07:00 | UK RNS | Synthomer PLC Trading statement - Autumn 2024 |
| 17/10/2024 | 15:01 | UK RNS | Synthomer PLC Holding(s) in Company |
| 14/10/2024 | 12:51 | UK RNS | Synthomer PLC Holding(s) in Company |
| 27/9/2024 | 11:46 | UK RNS | Synthomer PLC Holding(s) in Company |
| 19/9/2024 | 12:01 | UK RNS | Synthomer PLC Holding(s) in Company |
| 13/8/2024 | 11:22 | ALNC | Synthomer underlying operating profit up as divestment continues |
| 13/8/2024 | 06:00 | UK RNS | Synthomer PLC Interim results |
| 19/7/2024 | 05:56 | ALNC | Synthomer appoints outgoing Keller Chair Peter Hill as chair |
| 18/7/2024 | 11:53 | UK RNS | Synthomer PLC Chair succession and other board changes |
Synthomer (SYNT) Share Charts1 Year Synthomer Chart |
|
1 Month Synthomer Chart |
Intraday Synthomer Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/11/2024 | 16:06 | Synthomer | 1,661 |
| 14/8/2024 | 07:17 | Synthomer - formerly Yule Catto | 45 |
| 07/8/2018 | 18:23 | Synthomer (SYNT) One to Watch on Monday | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 17:09:13 | 171.80 | 4 | 6.87 | O |
| 16:54:29 | 172.80 | 4 | 6.91 | O |
| 16:39:32 | 172.80 | 10 | 17.28 | O |
| 16:35:24 | 171.20 | 63,899 | 109,395.09 | UT |
| 16:29:53 | 171.40 | 1 | 1.71 | AT |
| Top Posts |
|---|
Posted at 14/10/2024 06:25 by 100egs *UBS CUTS SYNTHOMER PRICE TARGET TO 205 (300) PENCE - 'NEUTRAL' |
Posted at 05/10/2024 16:40 by napoleon 14th Price reatcion turned out to be a damp fart, simmsc. |
Posted at 14/8/2024 16:11 by napoleon 14th Stockopedia on SYNT, 130824Paul’s opinion - I think this is still quite a big mess. Bulls must be hoping to see a dramatic improvement in future profitability, which is needed to reduce debt down to more normal levels. To me, risk:reward seems poor right now, with a mountain of debt to service, let alone repay. Cashflow looks very poor in H1, and wasn’t great last year either, with the only significant cash inflows coming from disposals, and the £266m equity fundraise last year. I reckon that probably won’t be the last equity raise. Remember I’m only analysing the basic numbers, not trying to predict how the business will perform in future. If you think there’s a spectacular turnaround opportunity here, then it might be worth taking on all the risk. Each 1% rise in profit margin is £20m extra profit - not bad if they can raise margins in an economic recovery. For me, it has to be AMBER/RED again, to flag that this is still an overly-indebted business, and it’s not trading very well either, with no particular upside yet apparent in the outlook comments either. Shareholders have to hope that changes for the better. Maybe I've missed something, as the StockRanks are mildly positive on this share - |
Posted at 14/8/2024 07:17 by bigbigdave *BERENBERG CUTS SYNTHOMER PRICE TARGET TO 340 (375) PENCE - 'BUY' |
Posted at 06/4/2024 11:28 by mirabeau Interesting and it seems informed comments from ION, dated end Fed 2024 :. It seems more disposables to reduce debt is on the cards and maybe a potential bid thrown into the pot to keep things bubbling :-- Synthomer lines up European carveouts for 2024, sources say 29th February 2024 07:49 AM By Kezia Joseph and Georgina Barnard Synthomer [LON:SYNT] is exploring several carveouts of its European assets, according to three sources familiar with the situation. The British chemicals business is looking to divest its Compounds and Paper Latex units, both of which sit within the wider Paper, Carpet & Foam division, according to all of the sources, with banks believed to have been selected to run an auction. According to one of the sources, Synthomer’s Compounding business is being marketed off EBITDA of GBP 10m, and the unit has sites in the Netherlands and Germany. One of the sources added that Synthomer may also consider offloading its Additive Solutions unit. The potential carveouts would follow Synthomer’s attempted sale of its William Blythe division last year. The inorganic materials unit was expected to be marketed off EBITDA of GBP 7m – GBP 8m, but interest in the sale has since waned. As previously reported, Synthomer’s SBR Latex and Acrylic Monomers operations have also been flagged as potential exit options. These units sit within Synthomer’s Health & Protection and Coatings divisions, respectively. The potential divestments come as Synthomer reported a drop in revenue across the board for its various units, according to its most recent financial report. Synthomer’s Coatings & Constructions Solutions division saw revenue drop to GBP 55.1m in 1H23 from GBP 80.3m the previous year while Health & Protection and Performance Materials saw revenue fall to GBP 11.3m in 1H23 from GBP 59.2m a year earlier, according to the company’s half-year 2023 report. Synthomer’s EBITDA fell to GBP 72m for 1H23 from GBP 162.8m a year earlier. In 2019, Synthomer launched a strategic review of its SBR latex operations, following which it decided to close its facilities in Finland and reduce production in Germany in response to declining demand. SBR latex is used for the coating of graphic and packaging paper, and the move to electronic media has put a strain on the paper market. At the end of 2022, Synthomer sold its OMNOVA laminates unit to Surteco Group [ETR:SUR]. The company’s share price sits at 146.8p as of today (February 29). The shares are down 20% year-to-date, for a GBP 240m market cap. Last month, this news service flagged Synthomer as a potential takeover target for 27% shareholder Kuala Lumpur Kepong, which attempted to acquire the business last year. Synthomer declined to comment. - |
Posted at 07/2/2024 10:59 by libertine EXPERT VIEW06 FEB, 2024 Berenberg recommends ‘buy’ Synthomer Specialist chemicals group Synthomer (SYNT) is at ‘the right time in the cycle for some action’, according to Berenberg. Analyst Sebastian Bray retained his ‘buy’ recommendation and target price of 320p on the Citywire Elite Companies A-rated stock, which fell 5.1% to 143.1p on Monday. Bray said the ‘key message’ from the trading update this month was that debt is down, with the corollary being that the shares increased ‘despite continued headwinds to the adhesives unit’ that saw earnings decrease modestly below consensus expectations. ‘Rising China chemicals imports and a recent bottoming of base chemicals prices in our view signal the start of a recovery in demand for chemicals in 2024,’ said Bray. ‘The pick-up in Synthomer’s volumes of nitrile latex in the fourth quarter appears consistent with the beginnings of a modest recovery, as reflected in the 12% rally in TopGlove shares since the start of December.’ He added that Synthomer is one of the ‘most levered to a macro recovery in European chemicals’. |
Posted at 12/1/2024 09:38 by libertine Berenberg cuts Synthomer price target to 320 (400) pence - 'buy' ?????????Berenberg lowers target price on Synthomer Fri, 12th Jan 2024 10:05 Analysts at Berenberg lowered their target price on chemicals business Synthomer from 400.0p to 320.0p on Friday as it lowered its operating profit expectations for 2023-25. Berenberg stated that cyclical stocks with high indebtedness "do not put investors at ease", noting that the more than 80% decline in Synthomer shares over the last 12 months was "a case in point". However, the German bank said it was "more optimistic". "The firm has a leverage problem, although not a liquidity issue. Last year's £276.0m rights issue has bought time to recover," said Berenberg. "Construction market headwinds mean that the company will, in our view, show minimal progress in organically cutting its absolute net debt pile, even allowing for self-help." Berenberg, which reiterated its 'buy' rating on the stock, noted that the moment a cyclical recovery, fast or slow, materialises, Synthomer shares should jump - perhaps as drastically as they have fallen. "We have reduced our operating profit forecasts by a high-single-digit percentage on average for 2023-25, mainly reflecting lower construction-linked margins and volumes. Shares trade on 2025 price-to-earnings ratio of 4.2x, compared to long-run average of around 11.0x. Our price target would imply circa 9.0x," added Berenberg. |
Posted at 11/1/2024 13:36 by darrin1471 LOTM "They allowed the £1B purchase to go ahead without proper financing to be in place at the time. A criminal decision."At the time of the acquisition (28/10/2021) BofE rates were 0.1%, we were exiting covid and the SYNT share price was near all time highs. Congratulations to all of those who had a crystal ball in 2021 and shorted SYNT. The share price was not a sudden collapse but a long 2 year fall. There was plenty of opportunity to sell. Small investors either took their eye off the ball or stuck their heads in the sand. I don't have a crystal ball but today the SYNT mkt cap looks good value, higher than average risk with higher than average potential reward. I still hold no position long or short in SYNT. |
Posted at 27/11/2023 22:40 by darrin1471 wigwammer. Thanks for the heads up on McBride 18 months ago. Last months rise makes it my biggest holding. I continue to hold MCB as I see further upside in re-valuation and even higher profits.I've had SYNT on a watch list for a few months and now the dust has settled I have taken a deeper look and I quite like the look of what I see. The strategy of a specialist chemicals company looks sound. The price SYNT paid for Omnova and Eastman’s Adhesive Resins looks reasonable. The Eastman’s timing is unfortunate but at the time of the acquisition (28/10/2021) BofE rates were 0.1%, we were exiting covid and the SYNT share price was near all time highs. The sale of non core business and the return of normal trading conditions should lead to a significant recovery. I hold no position in SYNT at the moment. |
Posted at 07/9/2023 11:24 by darrin1471 If I bought 10,000 shares today at 42p it would cost me £4200.Consolidation of share 20 to 1 would leave me with 500 shares worth £8.40 and the total value would remain £4200 6:1 rights issue at £1.97 would mean I could buy (6 x 500) 3000 at £1.97 costing £5910 I would end up with 3500 shares costing £10,110. Current shares in issue 467m x 42p share price is a mkt cap of £200m 467m shares consolidated at a rate of 20:1 would be 23.35m 23.35 x 6:1 rights issue would be 140m new shares issued as per announcement As of 8am 26/09/23 shares will be consolidated 20:1. I will end up with 500 shares trading at £8.40 (current price 42p x 20) If I still hold shares at the close of business of 26/09/23 I will be entitled to the 6:1 rights issue. On opening on 27/09/2023 share price will fall to £2.88. (((£1.97 x6) + £8.40)/7) I would have 3500 at £2.88 = £10,800 Valuation would obviously change with share price I am not in my comfort zone here. Does that sound right? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
